NasdaqCM - Nasdaq Real Time Price USD

SHL Telemedicine Ltd. (SHLT)

2.6900

-0.0300

(-1.10%)

As of 9:55:53 AM EST. Market Open.

DocGo and SHL Telemedicine partner to put 12-lead devices in health care units

DocGo (DCGO) announced an expanded partnership with SHL Telemedicine (SHLT) to integrate the SmartHeart portable 12-lead ECG device across DocGo mobile health care units. This expanded collaboration, initially launched in the New York-New Jersey area, will now bring advanced cardiovascular diagnostics to patients’ homes and underserved communities in additional markets across the country. According to the Journal of the American College of Cardiology, 46% of U.S. counties do not have any cardiol

TipRanks 27 days ago

SHLT
-1.10%
DCGO
DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

NEW YORK, December 18, 2024--DocGo Inc. (Nasdaq: DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced an expanded partnership with SHL Telemedicine (NASDAQ: SHLT) to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. This expanded collaboration, initially launched in the New York-New Jersey area, will now bring advanced cardiovascular diagnostics to patients’ homes and underserved communities

Business Wire 28 days ago

SHLT
-1.10%
DCGO
SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine

TEL AVIV & ZURICH & NEW YORK, July 29, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has announced today that it has appointed Mr. David Arnon as CEO of the Company. He will join SHL Telemedicine and assume the role on August 6, 2024, succeeding Erez Nachtomy, who, as previously announced, will step down as CEO.

Business Wire 5 months ago

SHLT
-1.10%
SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

TEL AVIV & ZURICH & NEW YORK, June 20, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has clarified today that it is in discussions with Discount Capital Ltd. the investment arm of Israel Discount Bank, regarding a possible investment relating to SHL’s Israeli activity. At this point, the parties have not yet taken any decision nor entered into any binding obligation with regard to th

Business Wire 6 months ago

SHLT
-1.10%
SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

TEL AVIV, Israel & ZURICH & NEW YORK, May 21, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is proud to announce that it has expanded its offering in Israel to include the groundbreaking ability to perform at-home Biomarker blood tests.

Business Wire 7 months ago

SHLT
-1.10%
SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

TEL AVIV, Israel & ZURICH, & NEW YORK, May 16, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is thrilled to announce that it recently officially launched it’s SmartHeart® membership program in the US.

Business Wire 7 months ago

SHLT
-1.10%
SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

TEL AVIV, Israel & ZURICH & NEW YORK, April 17, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation.

Business Wire 8 months ago

SHLT
-1.10%
Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care

TEL AVIV & ZURICH & NEW YORK, April 11, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial. The randomized clinical trial showcased, among other things, how SHL’s SmartHeart® 12-lead ECG technology can significantly reduce hospital readmissions and ED visits for post-MI (heart attack) pati

Business Wire 9 months ago

SHLT
-1.10%
SHL Telemedicine’s SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment

TEL AVIV, Israel & ZURICH & NEW YORK, April 08, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions is pleased to share that in a remarkable display of innovation and operational excellence, the Company’s SmartHeart®, portable 12-lead ECG technology showcased its unparalleled capabilities and successfully participated in Project Convergence – Capstone 4 (PC-C4), the largest, two-phase, "in-

Business Wire 9 months ago

SHLT
-1.10%
SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023

TEL AVIV, Israel & ZURICH & NEW YORK, April 05, 2024--SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET.

Business Wire 9 months ago

SHLT
-1.10%
SHL Telemedicine Receives Buy Rating with $11.00 Price Target

TEL AVIV, Israel & ZURICH & NEW YORK, March 14, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that Litchfield Hills Research, a leading equity research firm has initiated coverage of with a 'Buy' rating and an $11.00 price target. This price target represents a significant premium over the company's current share price, highlighting the firm's confidence in SHL

Business Wire 9 months ago

SHLT
-1.10%
Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine’s SmartHeart® Technology, to Be Presented at ACC 24

TEL AVIV, Israel & ZURICH & NEW YORK, February 01, 2024--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce that the full results of the Imperial College London TELE-ACS clinical trial have been selected for presentation at the prestigious American College of Cardiology's 24th Annual Scientific Session & Expo Late-Breaking Clinical Trials Sessions (ACC 24 LBCT) in Atlanta

Business Wire 11 months ago

SHLT
-1.10%

Performance Overview

Return	SHLT	MSCI WORLD
YTD	-1.10%	+0.39%
1-Year	-66.29%	0.00%
3-Year	-81.58%	+17.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SHL Telemedicine Ltd. (SHLT)

DocGo and SHL Telemedicine partner to put 12-lead devices in health care units

DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine

SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care

SHL Telemedicine’s SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment

SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023

SHL Telemedicine Receives Buy Rating with $11.00 Price Target

Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine’s SmartHeart® Technology, to Be Presented at ACC 24

Performance Overview